Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin vs Chemotherapy in BRCA-mutated or BRCAness Ovarian Cancer
NCT02903004Phase 3Completed
- Sponsor
- Policlinico Gemelli
- Start
- Apr 2016
- Primary completion
- Dec 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trabectedin in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC), sponsored by Policlinico Gemelli. Primary endpoint: Overall Survival at 4 years. Started Apr 2016; status: completed.
02
Drugs
trabectedin
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02903004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903004.